( )KDABD: Diagnostic: Needs (i) histologic injury, (ii) evidence of antibody-endothelial interaction, and (iii) donor specific antibody (g>0 and/or peritubular capillary>0, v>0) (C4d2/3 by IF and/or C4d>0 by IPEX, and or g+ptc ≥ 2 for C4d negative ABMR)(in presence of TCMR/borderline change/infection g must be at least 1 to use g+ptc sum criterion)
( ) C4d substituted by g+ptc ≥2 and g ≥1 (check mark if this criterion is used as substitute for C4d)
( ) DSA substituted by C4d (check mark if this criterion is being used as substitute for DSA)
( )KDChAB-A: Chronic active antibody-mediated rejection:
Needs chronic tissue injury, evidence of antibody-endothelial interaction, and donor specific antibody (cg>0 and/or new onset CV &/or electron microscopy) (C4d2/3 by IF, and/or C4d>0 by IPEX, and/or g+ptc ≥2 if C4d negative)
( ) KDChAB: Chronic antibody-mediated rejection:
Term used when there is absence of evidence of current/recent antibody-endothelial interaction, but chronic tissue injury and DSA are present.
( ) KDC4Dst: C4d staining without evidence of rejection: Needs all three of the following criteria: (i) g=0, v=0, cg=0, TMA=0, AKI=0, (ii) (C4d2/3 by IF and/or C4d>0 by IPEX, and (iii) absence of borderline change or TCMR.
( ) Borderline change (i1-3, t0-1) or (i0-1, t1-3), (v0)
( ) Acute rejection (specify g,i,t,v grades):
( ) KDAR1A: Banff Type 1A (i1-3, t2, v0)
( ) KDAR1B: Banff Type 1B (i2-3, t3, v0)
( ) KDAR2A: Banff Type 2A (i1-3, t0-3, v1)
( ) KDAR2B: Banff Type 2B (i1-3, t0-3, v2)
( ) KDAR3: Banff Type 3 (i1-3, t0-3, v3)
( ) KDCa-TCMR:chronic active TCMR (grade 1A, 1B, or II)